adapalene vs guselkumab
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of adapalene and guselkumab. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Differin
Tremfya
No summary available.
Tremfya is a medicine that can help treat plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. It works by blocking a protein in your body that causes inflammation.
Information not available.
Tremfya treats moderate to severe plaque psoriasis in adults and children 6 years and older who weigh at least 88 pounds. It also treats active psoriatic arthritis in adults and children 6 years and older who weigh at least 88 pounds. Tremfya can also treat moderately to severely active ulcerative colitis and Crohn's disease in adults.
Information not available.
Tremfya is a type of medicine called an interleukin-23 antagonist. It blocks a protein called IL-23 in your body. IL-23 causes inflammation, so blocking it can help reduce the symptoms of psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.
- • Dry skin
- • Contact dermatitis (skin rash)
- • Burning feeling on the skin where you put the medicine
- • Skin irritation
- • Upper respiratory infections (like a cold)
- • Headache
- • Injection site reactions (redness, pain, or swelling)
- • Joint pain
- • Bronchitis
- Dry Skin 44,990
- Skin Burning Sensation 41,633
- Acne 39,264
- Erythema 38,379
- Skin Irritation 26,225
- Accidental Exposure To Product 3,138
- Psoriasis 2,066
- Needle Issue 2,054
- Device Issue 1,748
- Device Malfunction 1,480
No specific warnings noted.
Tremfya can cause serious allergic reactions, including anaphylaxis, which can be life-threatening. Tell your doctor right away if you have any signs of an allergic reaction, like hives, trouble breathing, or swelling of your face, lips, tongue, or throat. Tremfya may also increase your risk of getting infections, including tuberculosis (TB). Your doctor should check you for TB before you start taking Tremfya and monitor you for signs of TB during and after treatment. Tremfya can also cause liver problems. Your doctor should check your liver enzyme and bilirubin levels before you start taking Tremfya and periodically during treatment.
No pregnancy information available.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if Tremfya will harm your unborn baby. There is a pregnancy registry to monitor outcomes in women exposed to Tremfya during pregnancy. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, calling 1-877-311-8972, or emailing MotherToBaby@health.ucsd.edu.
Also Compare, Nearby Drugs
Compare adapalene with
Compare guselkumab with
How to Read This adapalene vs guselkumab Comparison
adapalene is classified in the Retinoid (Topical) drug class, while guselkumab sits within the Anti-IL-23 Monoclonal Antibody class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are split between OTC and prescription status, which affects access and supervision.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, adapalene has 190,491 submissions while guselkumab has 10,486. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for adapalene or guselkumab.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.